BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A, Julamanee J, Chansung K, Sirijerachai C, Norasetthada L, Nawarawong W, Khuhapinant A, Siritanaratanakul N, Numbenjapon T, Prayongratana K, Chuncharunee S, Niparuck P, Suwanban T, Kanitsap N, Wongkhantee S, Pornvipavee R, Wong P, Makruasi N, Wannakrairot P, Assanasen T, Sukpanichnant S, Boonsakan P, Kanoksil W, Ya-in C, Kayasut K, Mitranun W, Warnnissorn N. Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. Hematological Oncology 2018;36:28-36. [DOI: 10.1002/hon.2392] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Wong Y, Meehan MT, Burrows SR, Doolan DL, Miles JJ. Estimating the global burden of Epstein-Barr virus-related cancers. J Cancer Res Clin Oncol 2021. [PMID: 34705104 DOI: 10.1007/s00432-021-03824-y] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Touma E, Antoun L, Hallit S, Nasr F, Massoud M, El Othman R, Chahine G. Non Hodgkin lymphoma in Lebanon: a retrospective epidemiological study between 1984 and 2019. BMC Public Health 2021;21:1820. [PMID: 34627178 DOI: 10.1186/s12889-021-11840-3] [Reference Citation Analysis]
3 Missaoui N, Mestiri S, Bouriga A, Abdessayed N, Belakhdher M, Ghammem M, Abdelkefi M, Mokni M, Hmissa S. Extranodal NK/T-cell lymphoma in Tunisia: clinicopathological features, immunophenotype and EBV infection. J Egypt Natl Canc Inst 2019;31:1. [PMID: 32372136 DOI: 10.1186/s43046-019-0002-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, Niparuck P, Chuncharunee S, Numbenjapon T, Prayongratana K, Kanitsap N, Wongkhantee S, Makruasri N, Wong P, Norasetthada L, Nawarawong W, Sirijerachai C, Chansung K, Suwanban T, Praditsuktavorn P, Intragumtornchai T; Thai Lymphoma Study Group. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Hematol Oncol 2019;37:578-85. [PMID: 31702065 DOI: 10.1002/hon.2687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
5 Lekdamrongkul P, Pongthavornkamol K, Molassiotis A, Sriyuktasuth A, Siritanaratkul N, Chansatitporn N. Exploring health-related quality of life among non-Hodgkin's lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand. Support Care Cancer 2021. [PMID: 33909148 DOI: 10.1007/s00520-021-06246-1] [Reference Citation Analysis]
6 Kim M, Hwang HS, Cho H, Yoon DH, Suh C, Park CS, Go H, Huh J. Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution. J Pathol Transl Med 2021;55:330-7. [PMID: 34465079 DOI: 10.4132/jptm.2021.07.25] [Reference Citation Analysis]
7 Nanthakwang N, Rattarittamrong E, Rattanathammethee T, Chai-Adisaksopha C, Tantiworawit A, Norrasethada L, Ya-In C. Clinicopathological study and outcomes of primary extranodal lymphoma. Hematol Rep 2019;11:8227. [PMID: 31871611 DOI: 10.4081/hr.2019.8227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Jung H, Huh J, Ko Y, Jeon YK, Yoon SO, Kim SH, Yang WI, Park G, Kim JH, Paik JH, Han JH, Cha HJ, Jang KY, Shin B, Kim Y, Kim JE, Choi YD, Park MG, Kim HK, Choi SJ, Kim BM, Lee JS, Chang H, Choe J, Min SK, Eom DW, Cho M, Yoo SB, Kim WY, Lee H, Choi IH, Chong YS, Lee HI, Lee HJ, Lee S, Kim H. Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study. J Hematopathol 2019;12:173-81. [DOI: 10.1007/s12308-019-00369-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
9 Anuar NA, Tey KWF, Ng SC, Teh AKH, Abdul Rahman MHF, Chong BP, Gan GG. Outcomes of high dose therapy and autologous haematopoietic stem cell transplantation for non-hodgkin lymphoma: A retrospective analysis in a resource-limited country. Int J Clin Pract 2021;75:e13823. [PMID: 33202073 DOI: 10.1111/ijcp.13823] [Reference Citation Analysis]
10 Irawan C, Iskandar M, Harahap AS, Rumende CM, Ham MF. MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP. CMAR 2022;Volume 14:925-35. [DOI: 10.2147/cmar.s345745] [Reference Citation Analysis]
11 Wudhikarn K, Bennani NN. How to Sequence Therapies in Peripheral T Cell Lymphoma. Curr Treat Options Oncol 2021;22:74. [PMID: 34213653 DOI: 10.1007/s11864-021-00873-w] [Reference Citation Analysis]
12 Wudhikarn K, Bunworasate U, Julamanee J, Lekhakula A, Ekwattanakit S, Khuhapinant A, Chuncharunee S, Niparuck P, Numbenjapon T, Prayongratana K, Kanitsap N, Wongkhantee S, Makruasi N, Wong P, Norasetthada L, Nawarawong W, Sirijerachai C, Chansung K, Suwanban T, Praditsuktavorn P, Intragumtornchai T. Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group. Journal of Geriatric Oncology 2020;11:62-8. [DOI: 10.1016/j.jgo.2019.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Aladily TN, Khreisat W, Ashukhaibi O, Alkhatib SM, Annab H, Tarawneh MS, Salman TS, Abu Farsakh H, Mahgoub R, Bustami N, Mansour AT, Aldeen AlRyalat S, Abbadi AS, Al-Fararjeh F, Sughayer M, Jaber O. The epidemiology of lymphoma in Jordan: A nationwide population study of 4189 cases according to World Health Organization classification system. Hematol Oncol Stem Cell Ther 2020:S1658-3876(20)30171-0. [PMID: 33212024 DOI: 10.1016/j.hemonc.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Nowakowski GS, Zhu J, Zhang Q, Brody J, Sun X, Maly J, Song Y, Rizvi S, Song Y, Lansigan F, Jing H, Cao J, Lue JK, Luo W, Zhang L, Li L, Han I, Sun J, Jivani M, Liu Y, Heineman T, Smith SD. ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. Future Oncol 2020;16:991-9. [PMID: 32250167 DOI: 10.2217/fon-2020-0176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]